A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad157 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Courtney Woolsey und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Ebolavirus, Hemorrhagic Fever, Ebola, Marburgvirus, Viral Vaccines. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
The family Filoviridae consists of several virus members known to cause significant mortality and disease in humans. Among these, Ebola virus (EBOV), Marburg virus (MARV), Sudan virus (SUDV), and Bundibugyo virus (BDBV) are considered the deadliest. The vaccine, Ervebo, was shown to rapidly protect humans against Ebola disease, but is indicated only for EBOV infections with limited cross-protection against other filoviruses. Whether multivalent formulations of similar recombinant vesicular stomatitis virus (rVSV)–based vaccines could likewise confer rapid protection is unclear.
Methods
Here, we tested the ability of an attenuated, quadrivalent panfilovirus VesiculoVax vaccine (rVSV-Filo) to elicit fast-acting protection against MARV, EBOV, SUDV, and BDBV. Groups of cynomolgus monkeys were vaccinated 7 days before exposure to each of the 4 viral pathogens. All subjects (100%) immunized 1 week earlier survived MARV, SUDV, and BDBV challenge; 80% survived EBOV challenge. Survival correlated with lower viral load, higher glycoprotein-specific immunoglobulin G titers, and the expression of B-cell–, cytotoxic cell–, and antigen presentation–associated transcripts.
Conclusions
These results demonstrate multivalent VesiculoVax vaccines are suitable for filovirus outbreak management. The highly attenuated nature of the rVSV-Filo vaccine may be preferable to the Ervebo “delta G” platform, which induced adverse events in a subset of recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
- Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
- Department of Viral Vaccine Development, Auro Vaccines, Pearl River, New York, USA.
Förderung
- NIAID NIH HHS
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- Galveston National Laboratory
- University of Texas Medical Branch
Zitieren
APA
Woolsey, C., Borisevich, V., Agans, K. N., O'Toole, R., Fenton, K. A., Harrison, M. B., Prasad, A. N., Deer, D. J., Gerardi, C., Morrison, N., Cross, R. W., Eldridge, J. H., Matassov, D., & Geisbert, T. W. (2023). A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad157
Vancouver
Woolsey C, Borisevich V, Agans KN, O'Toole R, Fenton KA, Harrison MB, et al. A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad157
BibTeX
@article{Woolsey2023,
author = {Woolsey, Courtney and Borisevich, Viktoriya and Agans, Krystle N and O'Toole, Rachel and Fenton, Karla A and Harrison, Mack B and Prasad, Abhishek N and Deer, Daniel J and Gerardi, Cheryl and Morrison, Nneka and Cross, Robert W and Eldridge, John H and Matassov, Demetrius and Geisbert, Thomas W},
title = {A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad157}
}
EUVIMED